Summary of prospective randomized studies in VTE
| Study . | DOAC . | Obesity weight cutoff, kg . | Study duration, mo . | n, obesity/N, total population (%) . | Efficacy outcome, % . | Safety outcome, %* . | ||
|---|---|---|---|---|---|---|---|---|
| DOAC . | VKA . | DOAC . | VKA . | |||||
| RECOVER (I/II)27 | Dabigatran | >100 | 6 | 832/5107 (16.3) | 4.1 | 3.6 | N/A | |
| EINSTEIN (DVT/PE)28,29 | Rivaroxaban | >90 | 12 | 2332/8281 (28.2) | 2.0 | 1.8 | 8.5 | 8.7 |
| AMPLIFY30 | Apixaban | ≥100 | 6 | 1017/5244 (19.4) | 2.2 | 3.5 | 0.19 | 1.9 |
| HOKUSAI31 | Edoxaban | >100 | 12 | 1265/8240 (15.4) | 3.6 | 3.5 | 8.8 | 8.3 |
| Study . | DOAC . | Obesity weight cutoff, kg . | Study duration, mo . | n, obesity/N, total population (%) . | Efficacy outcome, % . | Safety outcome, %* . | ||
|---|---|---|---|---|---|---|---|---|
| DOAC . | VKA . | DOAC . | VKA . | |||||
| RECOVER (I/II)27 | Dabigatran | >100 | 6 | 832/5107 (16.3) | 4.1 | 3.6 | N/A | |
| EINSTEIN (DVT/PE)28,29 | Rivaroxaban | >90 | 12 | 2332/8281 (28.2) | 2.0 | 1.8 | 8.5 | 8.7 |
| AMPLIFY30 | Apixaban | ≥100 | 6 | 1017/5244 (19.4) | 2.2 | 3.5 | 0.19 | 1.9 |
| HOKUSAI31 | Edoxaban | >100 | 12 | 1265/8240 (15.4) | 3.6 | 3.5 | 8.8 | 8.3 |
N/A, not available.
Safety outcome included major bleeding and clinically relevant nonmajor bleeding, except for AMPLIFY study, where only major bleeding was reported.